A Study of Real-world Use and Effectiveness of Cytoreductive Strategies for the Treatment of Second-line Polycythemia Vera in France
Key claim: A French real-world medical-chart study (2022–2023 initiators) aims to characterize which second-line cytoreductive agents are used in polycythemia vera, why physicians switch, and their effectiveness and adverse events of special interest.
Abstract
The aim of this study was to assess which cytoreductive treatments are currently administered in standard practice as second-line therapy to patients with polycythemia vera (PV) in France and to find out the reasons physicians switch treatments. In addition, the research aimed to describe real-world effectiveness of second-line cytoreductive therapies and the occurrence of adverse events of special interest.
Study data were collected from the medical charts of patients who initiated a second-line cytoreductive agent for the treatment of PV and received their first dose between 1 Jan 2022 and 31 Dec 2023.
Why this matters
A French real-world medical-chart study (2022–2023 initiators) aims to characterize which second-line cytoreductive agents are used in polycythemia vera, why physicians switch, and their effectiveness and adverse events of special interest.